2025 Feb. 13 - X.HEALTH JAPAN 2025 Q1, Ready, Set, Go!

Collaborating with Taiwanese MedTech MoleculeX

We are excited to welcome the Taiwanese MedTech company MoleculeX to our X.HEALTH JAPAN 2025 Q1 edition!

What issues is MoleculeX addressing?
Oral Mucositis, a severe side effect of cancer treatments, causes painful ulcers that hinder therapy.
MoleculeX's MuCover® Patch and MuCoat® Glue provide the world's first large-area wound dressing for oral mucosa. Licensed in Taiwan in 2023, it is now in post-market clinical trials at major medical centers and preparing for FDA and CE Mark applications.

As part of our X.HEALTH JAPAN initiative, MoleculeX will benefit through Q1 from a 「Team Extension」 composed of both cross-border Expansion and Japan Medical Sector fractional experts who will support the design of a tailored, actionable Go-To-Market Strategy for their medical solution to enter the Japanese Market.

X.HEALTH JAPAN is an initiative co-delivered by XBORDR, an encognize G.K. Service Line, and xCare Inc., designed to specifically help HealthTech/MedTech companies de-risk and accelerate their Japan expansion through an expert-guided, pragmatic and customized approach.

Should you wish to know more about MoleculeX or the X.HEALTH JAPAN initiative, please do not hesitate to contact us!